Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREFIPS: Somatostatin vs Octreotide for Pancreatic Fistula
NCT03000946Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2017
- Primary completion
- Feb 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatostatin in pancreatic fistula (POPF) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Postoperative Pancreatic Fistula Grade B or C at 90 days. Started May 2017; status: completed.
02
Drugs
somatostatin
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on NCT03000946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000946.